ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors




ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

• Submission based on three phase 2 trials where Daiichi Sankyo and AstraZeneca’s ENHERTU showed clinically meaningful responses across a broad range of tumors
• If approved, ENHERTU would become the first HER2 directed medicine and antibody drug conjugate to receive a tumor agnostic indication in the EU

TOKYO & MUNICH–(BUSINESS WIRE)–The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU^® (trastuzumab deruxtecan) for the treatment of adult patients with HER2 positive (immunohistochemistry [IHC] 3+) unresectable or metastatic solid tumors who have received prior treatment and have no satisfactory alternative treatment options.

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).

The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from three phase 2 trials including DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01 where ENHERTU demonstrated clinically meaningful responses across a broad range of tumors.

“ENHERTU has shown a clinically meaningful benefit across several studies in HER2 positive metastatic solid cancers and this validation by the EMA is an important first step toward bringing this medicine to these patients in the EU,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “We look forward to working with the EMA to potentially secure a tumor agnostic indication for ENHERTU in the EU, similar to several other regions of the world where this approval has been received.”

About DESTINY-PanTumor02

DESTINY-PanTumor02 is a global, multicenter, multi-cohort, open-label phase 2 trial evaluating the efficacy and safety of ENHERTU (5.4 mg/kg) for the treatment of previously treated HER2 expressing tumors, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic cancer or other tumors.

The primary efficacy endpoint of DESTINY-PanTumor02 is confirmed objective response rate (ORR) as assessed by investigator. Secondary endpoints include duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety, tolerability and pharmacokinetics. Results from DESTINY-PanTumor02 were published in the Journal of Clinical Oncology.

DESTINY-PanTumor02 enrolled 267 patients, including 111 HER2 positive (IHC 3+) adult patients, at multiple sites in Asia, Europe and North America. For more information about the trial, visit ClinicalTrials.gov.

About DESTINY-Lung01

DESTINY-Lung01 is a global phase 2, open-label, two-cohort trial evaluating the efficacy and safety of ENHERTU (6.4 mg/kg and 5.4 mg/kg) in patients with HER2 mutant (cohort 2, n=91) or HER2 overexpressing (defined as IHC 3+ or IHC 2+) (cohort 1 and 1a, n=90) unresectable or metastatic non-small cell lung cancer (NSCLC) who had progressed after one or more systemic therapies.

The primary endpoint is confirmed ORR by independent central review. Key secondary endpoints include DOR, DCR, PFS, OS and safety. Results from the HER2 mutant cohort were published in The New England Journal of Medicine and results from the HER2 overexpressing cohort were published in The Lancet Oncology.

DESTINY-Lung01 enrolled 181 patients, including 17 HER2 positive (IHC 3+) adult patients, at multiple sites in Asia, Europe and North America. For more information about the trial, visit ClinicalTrials.gov.

About DESTINY-CRC02

DESTINY-CRC02 is a global, randomized, two arm, parallel, multicenter phase 2 trial evaluating the efficacy and safety of two doses (5.4 mg/kg or 6.4 mg/kg) of ENHERTU in patients with locally advanced, unresectable or metastatic HER2 positive (IHC 3+ or IHC 2+/ in situ hybridization (ISH)+) colorectal cancer of BRAF wild-type, RAS wild-type or RAS mutant tumor types previously treated with standard therapy. The trial was conducted in two stages. In the first stage, patients (n=80) were randomized 1:1 to receive either 5.4 mg/kg or 6.4 mg/kg of ENHERTU. In the second stage, additional patients (n=42) were enrolled in the 5.4 mg/kg arm.

The primary endpoint is confirmed ORR as assessed by blinded independent central review. Secondary endpoints include DOR, DCR, investigator-assessed confirmed ORR, clinical benefit ratio, PFS, OS and safety. Results from DESTINY-CRC02 were published in The Lancet Oncology.

DESTINY-CRC02 enrolled 122 patients, including 64 HER2 positive (IHC 3+) adult patients, at multiple sites in Asia, Europe and North America. For more information about the trial, visit ClinicalTrials.gov.

About HER2 Expression in Solid Tumors

HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of various tissue cells throughout the body and is involved in normal cell growth.¹ In some cancers, the HER2 gene is amplified or the cells have activating mutations.² HER2 protein overexpression may occur as a result of HER2 gene amplification and is often associated with aggressive disease and poor prognosis.³

In the EU, HER2 directed therapies have been used to treat breast, gastric and lung cancers. Although HER2 is expressed in solid tumor types including biliary tract, bladder, cervical, endometrial, ovarian and pancreatic cancers, testing is not routinely performed in these additional tumor types and as a result, available literature is limited.² In these solid tumors, HER2 overexpression, classified as IHC 3+, has been observed at rates from 1% up to 31%.^4,5,6 Approximately 1% to 5% of patients with NSCLC have tumors with HER2 overexpression (IHC 3+).^4,7 In metastatic colorectal cancer, an estimated 2% to 4% of patients have tumors that are HER2 overexpressing (IHC 3+).^8,9 HER2 positive expression (IHC 3+) has been reported in approximately 4% to 28% of endometrial cancers and 1% to 5% of ovarian cancers.^{5,10,11,12,13}

About ENHERTU

ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, ENHERTU is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. ENHERTU consists of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

ENHERTU (5.4 mg/kg) is approved in more than 85 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization (ISH)+) breast cancer who have received a prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial.

ENHERTU (5.4 mg/kg) is approved in more than 85 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial.

ENHERTU (5.4 mg/kg) is approved in more than 40 countries/regions for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer, as determined by a locally or regionally approved test, that have progressed on one or more endocrine therapies in the metastatic setting based on the results from the DESTINY-Breast06 trial.

ENHERTU (5.4 mg/kg) is approved in more than 60 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, as detected by a locally or regionally approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 and/or DESTINY-Lung05 trials. Continued approval in China and the U.S. for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ENHERTU (6.4 mg/kg) is approved in more than 70 countries/regions worldwide for the treatment of adult patients with locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01, DESTINY-Gastric02 and/or DESTINY-Gastric06 trials. Continued approval in China for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ENHERTU (5.4 mg/kg) is approved in more than 10 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HER2 positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options based on efficacy results from the DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02 trials. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

About the ENHERTU Clinical Development Program

A comprehensive global clinical development program is underway evaluating the efficacy and safety of ENHERTU as a monotherapy or in combination or sequentially with other cancer medicines across multiple HER2 targetable cancers.

About the Daiichi Sankyo and AstraZeneca Collaboration

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU in March 2019 and DATROWAY^® in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of ENHERTU and DATROWAY.

About the ADC Portfolio of Daiichi Sankyo

The Daiichi Sankyo ADC portfolio consists of seven ADCs in clinical development crafted from two distinct ADC technology platforms discovered in-house by Daiichi Sankyo.

The ADC platform furthest in clinical development is Daiichi Sankyo’s DXd ADC Technology where each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca. Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939, a TA-MUC1 directed ADC, is being developed by Daiichi Sankyo.

The second Daiichi Sankyo ADC platform consists of a monoclonal antibody attached to a modified pyrrolobenzodiazepine (PBD) payload. DS-9606, a CLDN6 directed PBD ADC, is the first of several planned ADCs in clinical development utilizing this platform.

Ifinatamab deruxtecan, patritumab deruxtecan, raludotatug deruxtecan, DS-3939 and DS-9606 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established.

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

References

¹ Iqbal N, et al. Mol Biol Int. 2014;852748.

² Omar N, et al. Pathogenesis. 2015;2(3):1-9.

³ Pillai R, et al. Cancer. 2017;1;123(21): 4099-4105.

⁴ Yan M, et al. Cancer Metastasis Rev. 2015;34(1):157–164.

⁵ Buza N, et al. Modern Pathology. 2013;26(12):1605-12.

⁶ Gårdmark T, et al. BJU Int. 2005;95(7):982-6.

⁷ Zinner RG, et al. Lung Cancer. 2004;44(1):99-110.

⁸ Cecchi F, et al. J Clin Oncol. 2023;41(4).

⁹ Valtora E, et al. Mod Pathol. 2015;28(11):1481-91.

¹⁰ Semiz HS, et al. Turk Patologi Derg. 2023;39(1):55-63;

¹¹ Halle MK, et al. Br J Cancer. 2017;118(3):378-387

¹² Uzunparmak B, et al. Ann Oncol. 2023;34(11):1035-1046

¹³ Ersoy E, et al. Int J Gynecol Pathol. 2022;41(4):313-319

Contacts

Global/US:
Jennifer Brennan

Daiichi Sankyo

jennifer.brennan@daiichisankyo.com
+1 908 900 3183 (mobile)

EU:
Simone Jendsch-Dowé

Daiichi Sankyo

simone.jendsch-dowe@daiichisankyo.com
+49 (89) 78080 (office)

Japan:
Daiichi Sankyo Co., Ltd.

DS-PR_jp@daiichisankyo.com

Investor Relations Contact:
DaiichiSankyoIR_jp@daiichisankyo.com

EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch




EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch

• Galderma will present a wealth of data including new findings showing the impact of modern living on sensitive skin and insights from the largest global survey conducted on the condition
• Late-breaking data on Nemluvio’s^® (nemolizumab) mode of action in atopic dermatitis (AD) and long-term safety and efficacy data in prurigo nodularis (PN) and moderate-to-severe AD up to two years will also be presented, supporting its potential as a frontline treatment that addresses key disease symptoms^1-5
• The company will also host a symposium on itch, industry hubs on sensitive skin and acne, and multiple Meet the Expert sessions, demonstrating its ongoing commitment to healthcare professional education and clinical excellence

ZUG, Switzerland–(BUSINESS WIRE)–Galderma (SIX: GALD), the dermatology category leader, today announced it will unveil updates from its portfolio at the 34^th European Academy of Dermatology and Venereology (EADV) congress, taking place in Paris, September 17-20, 2025. Highlighting its commitment to addressing skin conditions across the dermatology spectrum, Galderma will present 12 abstracts, including data on sensitive skin, prurigo nodularis, and atopic dermatitis, and host a variety of events – from industry hubs on sensitive skin and acne, to a symposium on itch.

Unveiling the global landscape of sensitive skin

Galderma will present data from its robust research into sensitive skin, a growing global issue which now affects up to 70% of people worldwide – a 68% increase over the last 20 years.^6,7 Data from a first-of-its-kind real-world clinical study conducted in China by Galderma’s Global Sensitive Skin Faculty (GSSF) – a global network of dermatology experts dedicated to advancing sensitive skin research and education – will be presented, revealing the biological impact of modern living and associated environmental factors on individuals with sensitive skin.⁸ Full results from the study will be presented by GSSF members Prof. Adam Friedman, GSSF Co-Chair and Chair of Dermatology at The George Washington University, United States (U.S.); Dr. Aaron Farberg, Dermatologist and Mohs Surgeon, Baylor University Medical Center, U.S.; and Prof. Martina Kerscher, Head of Division of Cosmetic Sciences, University of Hamburg, Germany, at an industry hub, titled ‘Sensitive skin syndrome: A rising phenomenon linked to modern lifestyles and environmental changes’. The hub will take place on Friday, September 19 from 11:15 AM – 12:00 PM CET, Hub 2.12.

Findings from the largest global survey on the impact and prevalence of sensitive skin as reported by almost 17,000 participants will also be presented.⁷ This multi-continent investigation highlights the impact of sensitive skin and the need for targeted, region-specific interventions to optimize the care of individuals affected by the condition worldwide.⁷ Other data to be presented include the efficacy and tolerability of a gentle exfoliating hydroxy acid lotion in managing sensitive skin, as well as an evaluation of the key differences between sensitive skin and rosacea.

Galderma’s efforts to support people with sensitive skin spans from research and education to products, as evidenced by its flagship skincare brand, Cetaphil^®, which offers a range of solutions for people with sensitive skin.

Presenting data on Nemluvio’s mode of action and long-term benefit as a potential front-line therapy in prurigo nodularis and atopic dermatitis

Galderma will also be presenting seven abstracts on its first-in-class monoclonal antibody, Nemluvio, including late-breaking data from a skin and blood proteomic analysis of patients with moderate-to-severe atopic dermatitis.¹ These results will be presented on Friday September 19 at 3:15 – 3:30 PM CET in the Paris Nord room. Interim analysis data in prurigo nodularis showing continued improvements in itch intensity and skin lesions up to 100 weeks will also be shared on Wednesday September 17, 6:10 – 6:17 PM CET, Room E01 – E03.² Additional data will be presented on Nemluvio’s long-term safety and efficacy in moderate-to-severe atopic dermatitis, including in adolescents up to 56 weeks, and adolescents and adults up to 104 weeks also showing continued improvements in itch intensity and skin lesions.^3,9 These data reinforce Nemluvio’s safety and efficacy profile, following its approval in the United States, Europe and several other countries around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis.^2-5

Galderma will also host a symposium titled ‘Ditching the itch: Exploring the latest advances in atopic dermatitis and prurigo nodularis, targeting freedom from itch and long-term skin lesion control’ on Friday, September 19 from 1:00 – 2:00 PM CET, Room S03. Experts will discuss advancing treatment strategies in atopic dermatitis and prurigo nodularis, and the importance of understanding itch as the most urgent symptom to target as it severely affects patients’ quality of life in these diseases.^10,11

Showcasing dermatology leadership through expert engagements

Expert dermatologists will discuss approaches and advancements in the treatment of acne during an industry hub titled, ‘A holistic approach to acne and acne sequelae: Combining retinoids, CTMP™ and cosmetic corrective procedures’ on Thursday September 18 from 2:15 – 3:00 PM CET, Hub 2.07.

Galderma will also host a series of Meet the Expert sessions on atopic dermatitis at its booth (#EO1), including dedicated sessions titled ‘What would you do? A case-based discussion on atopic dermatitis treatment strategies’ on Thursday September 18; 12:00 – 12:30 PM CET and ‘Rethinking atopic dermatitis relief: Science-driven skincare solutions across the flare cycle’ on Thursday September 18 from 11:45 AM – 12:00 PM CET and Friday, September 19 from 2:00 – 2:15 PM CET.

More details on Galderma’s scientific presentations at EADV can be found here.

About Nemluvio

Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga^® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.^12,13 Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including the U.S. Food and Drug Administration and European Commission.^4,5 Additional reviews and submissions are ongoing.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Liu D, et al. Nemolizumab suppressed multiaxial inflammatory pathways and improved barrier protein signatures in skin and blood proteomic analysis of patients with moderate-to-severe AD. Late-breaking oral presented at the European Academy of Dermatology and Venereology (EADV) Congress; September 17-20, 2025; Paris, France
2. Metz M, et al. Clinically meaningful and sustained itch and skin responses in the OLYMPIA open-label extension nemolizumab study in patients with prurigo nodularis: An interim analysis up to 100 weeks. Poster presented at the EADV Congress; September 17-20, 2025; Paris, France
3. Nemluvio AD data. Silverberg J, et al. Nemolizumab long-term safety and efficacy up to 104 weeks in ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis. Poster presented at the EADV Congress; September 17-20, 2025; Paris, France
4. Nemluvio^® U.S. Prescribing Information. Available online. Accessed September 2025
5. Nemluvio^® European Medicines Agency. Summary of Product Characteristics. Available online. Accessed September 2025
6. Richters R, et al. What Is Sensitive Skin? A Systematic Literature Review of Objective Measurements. Skin Pharmacol Physiol. 2015;28(2),75-83. doi:10.1159/000363149
7. Vidal S, et al. Defining the Prevalence, Clinical Characteristics, and Demographic Influences on Patients with Sensitive Skin Syndrome: Insights from the Largest Global Survey of Sensitive Skin. Poster presented at the EADV Congress; September 17-20, 2025; Paris, France
8. Friedman A. Sensitive skin syndrome: A rising phenomenon linked to modern lifestyles and environmental changes. Presented during an industry hub at the EADV Congress; September 17-20, 2025; Paris, France
9. Reich A, et al. Long-term efficacy and safety of nemolizumab in adolescents with moderate-to-severe atopic dermatitis: Post hoc analyses from ARCADIA LTE 1-year cut-off. Poster presented at the EADV Congress; September 17-20, 2025; Paris, France
10. Aggarwal P, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277-1284. doi: 10.1111/ced.14722
11. Silverberg JI, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340-347. doi: 10.1016/j.anai.2018.07.006
12. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed September 2025
13. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed September 2025

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com
+41 21 642 76 43

Tubulis Strengthens Leadership Team with Appointment of Halley Gilbert as Chief Legal and Operating Officer




Tubulis Strengthens Leadership Team with Appointment of Halley Gilbert as Chief Legal and Operating Officer

MUNICH–(BUSINESS WIRE)–Tubulis today announced the appointment of Halley Gilbert, JD, as Chief Legal Officer and Chief Operating Officer (CLO/COO). Bringing over 20 years of transaction and operations experience in the biopharmaceutical industry, Ms. Gilbert will further expand Tubulis’ leadership capabilities at a pivotal stage of clinical and corporate development. In this newly created role, she will leverage her combined expertise as an attorney and seasoned biotech executive to shape Tubulis’ strategy and support the continued growth of the company’s U.S. presence. Ms. Gilbert will be responsible for legal and administrative functions and play a key role in executing strategic transactions for the company.

“Halley’s extensive legal and operational experience and deep commitment to supporting rapidly growing biotech companies make her an ideal addition to our team as we further expand our clinical and business operations,” said Dr. Dominik Schumacher, CEO and Co-founder of Tubulis. “Her industry know-how and strategic leadership will be instrumental as we advance our lead ADC candidates through clinical development and continue to expand our pipeline with new modalities.”

“ADCs are transforming the oncology landscape, and Tubulis is leading the way with its differentiated approach to ADC design,” said Halley Gilbert, JD, CLO and COO of Tubulis. “Their innovative platforms and exciting research ethos allow them to unlock the full therapeutic potential of this powerful drug class. I am thrilled to be joining such a motivated team and look forward to helping shape the path toward commercialization and delivering a meaningful clinical impact to patients.”

Ms. Gilbert brings extensive legal and operational experience within the life sciences industry, having served as CLO and COO at both public and private biotech companies. Most recently, she served as Chief Legal Officer of Cargo Therapeutics and played a key leadership role in the company’s initial public offering and subsequent sale. Prior to Cargo, Ms. Gilbert was the first employee of Invyvid, Inc. (formerly Adagio), where she enabled the company’s rapid growth from launch to IPO, and accelerated its transition from early R&D to late-stage clinical development. In addition, for the past five years, Ms. Gilbert has been a member of the Board of Directors at Vaxcyte, Inc., Arcutis Biotherapeutics, and CytomyX Therapeutics, Inc.

About Tubulis

Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. The two lead programs from our growing pipeline, TUB-040, targeting NaPi2b, and TUB-030, directed against 5T4, are being evaluated in the clinic in high-need solid tumor indications. We will solidify our leadership position by continuing to innovate on all aspects of ADC design leveraging our proprietary platform technologies. Our goal is to expand the therapeutic potential of this drug class for our pipeline, our partners and for patients. Visit www.tubulis.com or follow us on LinkedIn.

Contacts

For Tubulis
Dominik Schumacher, CEO & Co-founder

Phone: +49 (0) 175 800 5594

Email: contact@tubulis.com

Media Requests for Tubulis
Trophic Communications

Stephanie May, PhD

Phone: +49 (0) 171 185 56 82

Email: tubulis@trophic.eu

Abselion Launches AAVX and AAV9 Total Capsid Quantification Kits




Abselion Launches AAVX and AAV9 Total Capsid Quantification Kits

• Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
• Kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents for enhanced specificity and consistency

CAMBRIDGE, United Kingdom–(BUSINESS WIRE)–#AAV–Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering, with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit. Both kits are designed for use with its Amperia™ benchtop quantification platform and include Thermo Fisher Scientific’s CaptureSelect™ affinity reagents. Combining these trusted reagents with Abselion’s consistent assay format reduces the need for in-house optimisation. These kits offer researchers working in adeno-associated virus (AAV) development and characterisation a more streamlined and accessible workflow to generate reproducible titre measurements across a broad range of serotypes and process conditions.

Abselion’s Amperia benchtop platform is a simple-to-use solution for rapid and accurate automated quantification of a range of biomolecules, without optics, fluidics, or specialist training. Each kit is supplied in a ready-to-use format, including sensor strips, assay plates, matched detection reagents, and assay buffers for the binding and detection steps. The expanded kit range enhances the utility of Amperia for scientists working across gene therapy development and process workflows, offering a practical, dependable approach to total capsid quantification from purified or complex samples.

Abselion has entered into a licensing agreement with Thermo Fisher Scientific to incorporate CaptureSelect affinity reagents into its AAV quantification kits. CaptureSelect technology is based on recombinant single-domain antibodies designed for high target specificity, low cross-reactivity, and consistent batch performance to ensure robust titre quantification. With the integration of these reagents, the new kits advance Abselion’s AAV assay format, bringing improved performance and broader serotype applicability.

Both kits use a sandwich-style immunoassay format, in which biotin- and HRP-conjugated CaptureSelect antibodies are sequentially applied to bind AAV capsids. The resulting signal is detected electrochemically using Amperia sensor strips, enabling accurate quantitative detection across a range of AAV sample types and concentrations.

The AAVX Total Capsid Quantification Kit includes CaptureSelect Anti-AAVX Biotin and HRP Conjugates, enabling broad serotype coverage including AAV1–8 and AAVrh10. The AAV9 Total Capsid Quantification Kit incorporates CaptureSelect Anti-AAV9 Biotin and HRP Conjugates for focused quantification of AAV9 particles.

Dr Ruizhi Wang, CEO and Founder, Abselion, said: “Reliable quantification of total AAV capsid concentration is key to maintaining consistency and supporting informed decision-making. The integration of Thermo Fisher Scientific’s CaptureSelect reagents strengthens the performance of Abselion’s AAV kits and reflects our focus on making high-quality titre measurement simpler and more accessible. With these additions, Amperia offers researchers a ready-to-use solution that combines trusted reagent technologies with a streamlined assay format, enabling reliable quantification across a wider range of serotypes and development workflows.”

Dr Kelly Flook, Sr. Manager, Product Management, Pharma Analytics, Thermo Fisher Scientific, said: “CaptureSelect affinity reagents are designed to deliver high specificity and lot-to-lot consistency, making them well suited for applications such as AAV capsid quantification. We’re pleased that Abselion has incorporated these reagents under licence to support their assay kits for the Amperia platform.”

For further information about Abselion’s AAVX and AAV9 Total Capsid Quantification Kits, please visit: https://www.abselion.com/assay-kits/ or download the application note “Empowering AAV Quantification for Gene Therapy Research”. The Abselion team will also be attending Festival of Biologics (30 Sep–02 Oct in Basel, Switzerland). Meet the team at booth 240 to learn more.

Please contact Codon Communications for high-resolution images.

Contacts

Codon Communications
Dr Michelle Ricketts

Tel: +44 7789 053885

Email: michelle.ricketts@codoncommunications.com

‘RevoAb™’, A New Service for Antibody Developability Engineering




‘RevoAb™’, A New Service for Antibody Developability Engineering

SENDAI, Japan–(BUSINESS WIRE)–RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein^® is pleased to announce the launch of a new contract research service, ‘RevoAb™’. This service engineers antibodies to improve physicochemical properties while protecting antigen binding affinity.

About RevoAb™

Since December 2023, RevolKa has offered contract research services for antibody engineering using aiProtein^®, its AI-driven protein engineering technology, through FUJIFILM Wako Pure Chemical Corporation in Japan.

RevoAb™ is a new online service for antibody developability engineering based on “RevolKa’s Refined Naturalness Design concept,” This refines antibody framework sequences to be close to those in naturally occurring antibodies. The pilot version was released in Japan in July 2025. Based on customer feedback, we are now launching an upgraded RevoAb™ world-wide.

With RevoAb™, users can instantly access multiple antibody sequences with potential improvement in properties, such as expression levels, stability, solubility, etc., at low prices.

For more details, please visit.:

https://revoab.revolka.com/en/

Story behind RevoAb™ Development.

Antibodies are proteins that provide immune protection by recognizing and binding to substances (antigens) from infecting bacteria and viruses. They are widely used in industries, such as therapeutics and diagnostics. However, antibodies are often fragile for industrial applications, and enhancing their properties typically requires significant time and resources.

RevolKa has successfully engineered many proteins using aiProtein^® in collaboration with customers. For antibodies, we identified that part of aiProtein^® could become a valuable tool for scientists struggling with suboptimal physicochemical properties. It is engineering of framework sequences of antibody by using RevolKa’s Refined Naturalness Design concept. We developed RevoAb™ to provide research scientists with “Winning Antibody Sequences” instantly online.

Fees

Registration

Please review and agree to the terms of use and privacy policy before filling out the form on the landing page.

Contacts

Inquiries Regarding RevoAb™
For any question, please contact us at support-revotune@revolka.co.jp

A.forall expands US generics portfolio




A.forall expands US generics portfolio

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach

ANDERLECHT, Belgium–(BUSINESS WIRE)–#FocusToGrow–A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm’s US portfolio. With this acquisition, A.forall considerably extends its marketed portfolio in the US, marking a significant expansion of its US footprint and a key milestone in the company’s sharpened focus on high-quality generics worldwide.

Strengthening Essential Healthcare

The acquired portfolio includes four well-established hospital products that address critical therapeutic needs:

• Dihydroergotamine Mesylate (neurology – for the treatment of migraine and cluster headaches)
• Piperacillin/Tazobactam (infectious disease – broad-spectrum antibiotic for hospital-acquired infections)
• Tranexamic Acid (hematology – to control bleeding in surgical and trauma settings)
• Phenylephrine Hydrochloride (anesthesiology – to manage hypotension during surgery)

These medicines are widely integrated in US hospital protocols and marketed via established pharmaceutical distributors and group purchasing organizations, ensuring strong clinical familiarity among healthcare professionals. The newly acquired products will be commercialized through A.forall’s US subsidiary, Milla Pharmaceuticals Inc.

The two late-stage pipeline products target complementary therapeutic areas and are expected to launch in the coming years.

Steen Vangsgaard, CEO of A.forall, comments: “This acquisition fits perfectly with our renewed strategy to develop, commercialize and add value to medicines, increasing their availability where they matter most. These products expand our US relevance and give us immediate access to a robust portfolio that meets essential therapeutic needs. It’s a strategic investment that delivers scale, diversification and valuable cross-selling opportunities.”

Strategic US Focus

For A.forall, the US is a strategic priority. With a dedicated team on the ground, strong partnerships and a robust pipeline, the company continues to invest in one of the world’s most competitive and complex healthcare environments.

Since 2017, six products of A.forall were registered successfully in the US market, demonstrating consistent growth and commitment to American healthcare providers.

“By integrating this portfolio with our existing capabilities, we focus to reach further into markets where high-quality generic medicines make the greatest difference,” Vangsgaard adds. “This acquisition strengthens our brand recognition and significantly expands our commercial presence in the world’s largest pharmaceutical market.”

This acquisition follows the recent decision to divest A.forall’s Retail & Hospital division and focus entirely on generics: a strategy that gives the company a sharper scope, stronger momentum and a clear direction for growth.

About A.forall

A.forall is a Belgian pharmaceutical group with headquarters in Anderlecht and offices in Ireland and the United States. At current, the company employs over 144 people and distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals and retirement homes. A.forall is also a global player in the generics market, now with 35+ molecules on the European and U.S. market and a fully stocked pipeline of mainly injectable generics and value-added products covering various therapeutic areas.

Driven by one mission #MakingAffordableMedicinesAvailableToAll, A.forall focuses 100% on the development, licensing and commercialization of generic medicines worldwide.

A.forall is part of The Riverside Company’s portfolio, a global investment firm focused on the smaller end of the middle market that has invested in more than 220 healthcare companies since 1988.

For more information, visit: www.aforallpharma.com.

Contacts

We’re happy to provide additional context or answer any questions you may have.

For media inquiries or more information, please contact:

A.forall Group NV

Communication Department
communications@aforallpharma.com
+32 2 526 64 14

New Arizona’s Bioscience Roadmap Details How the State Becomes a Nationally Recognized Bioscience Hub




New Arizona’s Bioscience Roadmap Details How the State Becomes a Nationally Recognized Bioscience Hub

• The Flinn Foundation has commissioned a new Arizona’s Bioscience Roadmap to guide discovery, innovation, and economic growth through 2030
• The strategic plan was first launched more than two decades ago and includes goals for accelerating commercialization, empowering startups, and developing and retaining workers
• Developed by SRI International of Menlo Park, Calif., the plan will be launched at stakeholder events statewide and online the week of Sept. 8, 2025

PHOENIX–(BUSINESS WIRE)–#AZBioRoadmap–A new blueprint for Arizona’s emerging bioscience ecosystem lays out a plan for the state to capitalize on more than two decades of momentum and become a nationally recognized leader in the space.

The next iteration of Arizona’s Bioscience Roadmap, which will be unveiled the week of Monday, Sept. 8, builds on Arizona’s skilled talent base, world-class research, and entrepreneurial spirit to improve the economy as well as Arizonans’ health and quality of life.

The report analyzes Arizona’s strengths and challenges, acknowledging the uncertainty around federal funding for bioscience research and how that may impact the state going forward.

More than 140,000 people are employed in bioscience companies and hospitals in Arizona. On average, their salaries are 30% higher than private-sector salaries statewide. Crossover opportunities with semiconductor manufacturing and other tech-heavy industries provide a key opportunity for growth in the next five years, the Roadmap concludes.

Medical device manufacturing, neuroscience, oncology, and precision medicine are among the areas of particular excellence and promise in Arizona.

“With the right vision, strategies, determination, and courage — and with its rapidly growing resources, existing and potential strengths, and remarkable collaborative spirit — Arizona has a chance to make transformational contributions to bioscientific research and clinical care, with a profound impact on people here in Arizona and around the world,” said Dr. Eric Reiman, chair of the Flinn Foundation board of directors.

“The Flinn Foundation is excited to help in that endeavor.”

The Bioscience Roadmap is the longest-running statewide bioscience strategic plan in the nation. It was launched by the Flinn Foundation in 2002. Since then, the Foundation has tracked and publicly reported performance metrics from the six subsectors that make up the Arizona biosciences:

• Agricultural feedstock and industrial biosciences
• Bioscience-related distribution
• Medical devices and equipment
• Pharmaceuticals
• Research, testing, and medical laboratories
• Hospitals

The most recent report from April 2025 showed Arizona’s growth rate continues to outpace the nation in several categories, including bioscience jobs, National Institutes of Health funding, and university research and development, and included several record highs for the state.

The new Roadmap, developed by SRI International in collaboration with Arizona leaders and commissioned by the Flinn Foundation, establishes five goals:

1. Amplify the collaborative gene: Arizona’s collaborative culture is something to be celebrated and leveraged. Unlike more entrenched regions, Arizona organizations and participants see how facilitating one another’s individual success helps the entire ecosystem. Collaboration can also accelerate innovation across technology sectors.

2. Accelerate research into impact: Arizona will increase the scale, speed, and success of commercialization of discoveries that address critical needs. Getting new treatments and products to patients quickly is vital, especially where they enable transformative improvements in quality of life.

3. Elevate Arizona’s startup ecosystem: The state will nurture and empower entrepreneurs and startups, providing resources and support to launch, scale, and retain bio ventures. An increasingly vibrant startup community will attract investors and global-scale bioscience firms.

4. Strengthen talent and career pathways: Arizona will attract, develop, and retain top professionals and skilled workers. A large, skilled and sustained talent pool is necessary to help home-grown startups thrive and attract out-of-state companies to Arizona.

5. Tell Arizona’s bioscience story: Arizona will be recognized nationally for its contributions to health outcomes and economic growth and a competitive policy environment.

The plan emerged from more than a year of research, interviews, and focus groups throughout the state.

“The Roadmap was shaped by the people of Arizona and belongs to the people of Arizona,” said Tammy McLeod, Ph.D., Flinn Foundation president and CEO.

“This plan is more than just a well-researched document; it serves as a living guide and inspiration for our leading researchers, entrepreneurs, policymakers, and educators as well as the students who can see a future for themselves in the biosciences here in Arizona.”

Christiana McFarland is the director of SRI’s Center for Innovation Strategy and Policy, which produced the report.

“Executing this Roadmap will require focus and collaboration among key partners. Doing so will strengthen Arizona’s economy, improve health outcomes, and cement the state’s place as a vital contributor to bioscience in the United States and beyond,” McFarland said.

Read the full Arizona’s Bioscience Roadmap report and executive summary: https://www.flinn.org/bioscience/arizonas-bioscience-roadmap/about-the-roadmap/

About the Flinn Foundation

The Flinn Foundation is a privately endowed, philanthropic grantmaking organization established in 1965 by Dr. Robert S. and Irene P. Flinn to improve the quality of life in Arizona to benefit future generations. Based in Phoenix, the Foundation supports the advancement of the biosciences in Arizona as well as the merit-based Flinn Scholarship, arts and culture, and the Arizona Center for Civic Leadership.

Contacts

Stacy Sullivan, Vice President, Communications, Flinn Foundation, 602-320-1762, ssullivan@flinn.org

Brian Powell, Communications Manager, Flinn Foundation, 602-744-6806, bpowell@flinn.org

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors




Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors.

“We are pleased to welcome John to our Company’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to drive innovation will be an incredible asset to Johnson & Johnson as we continue to deliver the next generation of healthcare innovation for patients.”

“I’ve long admired Johnson & Johnson for its innovation, leadership in healthcare and commitment to patients around the world,” said John Morikis. “I’m honored to join Johnson & Johnson’s Board and look forward to working with management and fellow directors to support the Company’s long-term strategy of delivering breakthrough treatments to patients and creating value for shareholders.”

About John Morikis

Mr. Morikis is the retired Executive Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, a global leader in the manufacture, development distribution and sale of paint, coatings, and related products.

He joined Sherwin-Williams in 1984 as a management trainee in the Paint Stores Group. Over the next four decades, he advanced through key leadership roles, including Division President and Group President. From 2006 to 2016, Mr. Morikis served as President and Chief Operating Officer before being appointed Chief Executive Officer, a position he held for eight years.

As CEO, Mr. Morikis led Sherwin-Williams through a strategic transformation that strengthened its market leadership and positioned the company for long-term success. He spearheaded a company-wide overhaul to differentiate Sherwin-Williams from industry commoditization by emphasizing world class talent, breakthrough innovation, customer-driven solutions, and a focus on value-added products and services. Under his leadership, the company expanded its global presence to 123 countries, optimized its supply chain, and invested in technology to enhance the customer experience and operational efficiency. These efforts reinforced Sherwin-Williams’ competitive edge, culminating in its inclusion in the Dow Jones Industrial Average and further solidifying its status as a global industry leader.

Mr. Morikis currently serves on the Board of Directors of United Parcel Service, Inc., General Mills, Inc. and Whirlpool Corporation and as Chairman of the Board of Directors for University Hospitals Health System, Inc.

He earned bachelor’s degrees in Business Administration and Psychology from Saint Joseph’s College in Rensselaer, Indiana, and a master’s degree in Business from National Louis University in Evanston, Illinois.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:

investor-relations@its.jnj.com

Corner Therapeutics Research Opens Path to Universal, Long-Lasting Flu Vaccine and Signals Promise for Oncology




Corner Therapeutics Research Opens Path to Universal, Long-Lasting Flu Vaccine and Signals Promise for Oncology

WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics, an in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection, today published research in mBio, a leading microbiology journal, showing that a novel technology to generate T cells in vivo significantly outperforms standard influenza vaccine adjuvants.

The study shows that the technology elicits a broadly acting immune response that targets all strains of influenza present in the commercial quadrivalent influenza vaccine Afluria. This finding may open the door for the development of a universal flu vaccine that could eliminate the need for annual immunization. Beyond influenza, the study serves as proof-of-concept for Corner’s technologies for oncology, where the generation of robust and durable T cell responses is critical for treating cancer.

In this study, the scientists at Corner discovered a new class of drugs, called hyperactivators, which engage nature’s T cell engineers in vivo, the dendritic cells. When used in vaccine settings in non-human primates, the influenza vaccine Afluria was converted into a universal formulation capable of targeting all virus strains – all while maintaining excellent safety margins.

“Our hyperactivator technology addresses a fundamental challenge for vaccines: how to protect people from broad strains of a virus while providing a durable, lifelong immune response,” said Jonathan Kagan, Distinguished Scientist at Corner Therapeutics. “This research validates a central dogma in immunology, that dendritic cells are the best conduit to robust T cell responses and immunity. This work not only moves us one step closer to a universal influenza vaccine that could eliminate the need for annual shots, but also provides proof-of-concept for our approach to cancer immunotherapies, where T cell activities are key to tumor eradication.”

Revolutionary Approach to Vaccine Enhancement

Corner’s hyperactivator technology was tested in both mice and non-human primates, where it enhanced cross-strain antibody responses and generated robust T cell memory. Unlike existing adjuvants such as aluminum hydroxide (Alum), Corner’s hyperactivators do not kill dendritic cells, but rather instruct these apex regulators of immunity to generate long term memory. This innovative approach represents a fundamental shift in how immunotherapies can be optimized for maximum health.

Corner Therapeutics aims to begin clinical trials of its hyperactivator technology by the end of 2027.

In addition to the hyperactivator technology, Corner Therapeutics is advancing its DCITE (Dendritic Cell Initiated T cell Engineering) platform to instruct dendritic cells to stimulate durable T cell immunity. Using lipid nanoparticle formulations to deliver mRNA encoding specific antigens directly to dendritic cells, DCITE enables the in vivo generation of tumor-specific CD8+ T cells to treat existing cancers and infections.

About Corner Therapeutics

Corner Therapeutics is the in vivo T cell modulation and immunotherapy company pioneering novel approaches to cancer and infection. Using its novel dendritic cell stimuli platforms, Corner teaches the immune system to engineer its own long-lived, disease-fighting T cells. With its antigen-agnostic platform, Corner is revolutionizing care for an exceptionally wide range of diseases. For more information about Corner Therapeutics, visit https://cornertx.com/

Contacts

Media: Mission North cornertherapeutics@missionnorth.com

Aptar Increases Quarterly Dividend by Nearly 7% Signaling Continued Momentum and Long-Term Strength




Aptar Increases Quarterly Dividend by Nearly 7% Signaling Continued Momentum and Long-Term Strength

Following an increase of almost 10% a year ago

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.48 per share, an almost 7% increase from the previous dividend amount, bringing the new annualized dividend to $1.92 per share. The payment date is November 13, 2025, to stockholders of record as of October 23, 2025.

Stephan B. Tanda, Aptar President and CEO, commented, “Given the strength of our business outlook, the sustained long-term growth we anticipate from our Pharma segment, and our continued strong performance across all key financial metrics, the Board of Directors has approved an increase in the quarterly dividend. Since 2020, we’ve returned over $1 billion to shareholders through dividends and share repurchases, and we remain on track to achieve our 32^nd consecutive year of increasing our total annual dividend.”

As previously announced, Aptar will hold its biennial Investor Day on Tuesday, September 9, 2025. The event will begin at 9:00 a.m. EDT. Presentations by members of executive management followed by a moderated Q&A session are expected to conclude at approximately 12:00 p.m. EDT. The general public can access the event and listen live by registering for the webcast.

About Aptar

Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

This press release contains forward-looking statements, including regarding our annualized dividends. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investor Relations Contact:
Mary Skafidas

mary.skafidas@aptar.com
+1 347-351-6407

Media Contact:
Katie Reardon

katie.reardon@aptar.com
+1 815-479-5671